Genomic Health Inc. (NASDAQ:GHDX)’s share price dropped 3% during mid-day trading on Monday . The company traded as low as $28.53 and last traded at $28.75, with a volume of 155,165 shares. The stock had previously closed at $29.65.

GHDX has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday. Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 price target on shares of Genomic Health in a research report on Friday. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a report on Thursday, May 26th. Finally, Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a report on Wednesday, August 3rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $32.22.

The firm’s market cap is $954.14 million. The company’s 50 day moving average is $27.52 and its 200-day moving average is $26.84.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The business earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.29) EPS. On average, equities research analysts anticipate that Genomic Health Inc. will post ($0.46) EPS for the current year.

In other news, insider Phillip G. Febbo sold 6,324 shares of the firm’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $27.20, for a total value of $172,012.80. Following the sale, the insider now directly owns 15,113 shares in the company, valued at approximately $411,073.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven Shak sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $25.77, for a total transaction of $128,850.00. Following the completion of the sale, the insider now owns 332,107 shares in the company, valued at $8,558,397.39. The disclosure for this sale can be found here.

Several large investors have recently made changes to their positions in the stock. Russell Frank Co raised its stake in shares of Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock worth $3,517,000 after buying an additional 76,416 shares during the last quarter. Royce & Associates LLC raised its stake in shares of Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock worth $2,341,000 after buying an additional 31,500 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Genomic Health during the fourth quarter worth $6,097,000.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.